Project Grant R61CA291168
Award Date
4/1/25
Completion Date
3/31/28
Dollars Obligated
$221K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), aims to develop an intervention against colorectal cancer (CRC) associated with colibactin-producing bacteria. The $627,422 award to the Regents of the University of Michigan will fund research to engineer E. coli bacteria to display an enzyme that neutralizes the carcinogenic colibactin toxin. The project will optimize the surface display of this anti-toxin...
This $449,726 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports the development of novel tools to enable the rapid, high-sensitivity mapping of dynamic changes in protein interactions occurring within living cells. The project aims to create three orthogonal methods that can biotinylate proteins within one minute or less, significantly improving the temporal resolution and signal-to-noise ratio compared to existing...
The National Cancer Institute awarded a $407,113 Project Grant (CFDA 93.396 - Cancer Biology Research) to Trustees of Boston University for the development of bio-orthogonal mid-infrared photothermal imaging technology to study cancer metabolism. This 3-year award, running from September 1, 2024 to August 31, 2027, aims to: 1) build a library of nitrile-based probes to sense molecular events in cancer cells; 2) develop nitrile-tagged small molecules to measure nutrient metabolism; and 3)...
This $1,355,273 Project Grant was awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to the Regents of the University of Michigan. The grant funds the development of two complementary approaches to inhibit the production of the bacterial metabolite colibactin, which has been linked to colorectal cancer and microbiome dysbiosis.
The first approach involves enzymatic inactivation of colibactin through...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding of $424,734.00 to the University of Illinois to develop a novel spatial proteomics approach that integrates 3D microscopy techniques with bottom-up proteomic assays. This innovative method will enable deep proteome profiling of specific immune cells located in different subregions of a tumor. The key product will be a workflow to spatially encode and analyze immune cell...
The National Cancer Institute (NCI) awarded a five-year, $626,893 Project Grant (CFDA 93.396 - Cancer Biology Research) to The University of Texas MD Anderson Cancer Center to investigate the role of bacterial-colonized microniches within tumors and their impact on intratumoral heterogeneity and cancer progression. The project aims to functionally map the cellular and metabolic features of these bacterial-colonized microniches in patient tumor tissues, delineate the human cell types harboring...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research at the University of Chicago focused on developing genetically-engineered Bifidobacterium bacteria to overcome therapy resistance in metastatic pancreatic ductal adenocarcinoma. The $581,087 award, effective July 1, 2024 through June 30, 2029, will investigate administering the engineered Bifidobacterium to deliver a novel human IL-2 protein to the tumor...
This Project Grant award of $400,890, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports research to profile patient-specific tumor-microbiome interactions and conduct molecular analyses to elucidate microbiome-mediated modulation of immune checkpoint molecules in mismatch repair-proficient, microsatellite-stable colorectal tumors. The research team at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University will utilize...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $253,405 to support research and training activities at Columbia University's Health Sciences Division aimed at improving bacterial cancer therapeutics. The project seeks to identify key pathways that allow E. coli bacteria to selectively migrate to and colonize tumor tissues, which could lead to more effective cancer treatment approaches using bacteria as delivery vehicles....
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) totaling $537,985 will support research to deeply characterize the spatial distribution, functionality, and role of microbes within the tumor microenvironment of primary pancreatic ductal adenocarcinoma (PDAC) tumors and their influence on metastasis to the liver. The five-year project, awarded to the University of Texas MD Anderson Cancer Center, will utilize state-of-the-art...